American Diabetes Association Pathway to Stop Diabetes 2022
|To:||Chairs and Administrators, Departments in the Biological & Physical Sciences; Associate Deans for Research; College/School Research Administrators|
|From:||Office of the Vice Chancellor for Research & Graduate Education|
|Date:||May 11, 2022|
|Subject:||American Diabetes Association Pathway to Stop Diabetes 2022|
|Deadline for Internal Review:||June 08, 2022|
This announcement has been archived and replaced by American Diabetes Association Pathway to Stop Diabetes 2023
With over 37 million Americans living with diabetes and nearly 96 million more at increased risk of developing the disease, diabetes is a tremendous burden for the nation. Despite the disease’s epidemic proportions, diabetes research remains critically underfunded. Although researchers have made significant strides against the disease, funding is vital for continued progress.
To accelerate the research needed to stop this deadly disease, the American Diabetes Association’s bold transformational initiative, Pathway to Stop Diabetes (“Pathway”), is inspiring a new generation of diabetes researchers. Pathway provides crucial support to individuals focusing on innovative ideas and transformational approaches that will lead to ground–breaking discoveries in diabetes prevention, management and cure.
This call for nominations is prioritizing exceptional investigators that aim to advance existing knowledge and discovery gained from the basic sciences to its eventual translation into patient and population benefit. The ideal applicant will propose innovative research that will be an important step towards the eventual goal of improving the lives of people at risk of diabetes or living with the disease. Providing a pathway for realizing this impact is viewed as a critical component of this round of applications.
Nominations are welcomed from all areas of diabetes translational research and span prevention, management and cure of all diabetes types (type 1, type 2 and gestational), diabetes–related disease states (obesity, prediabetes, and other insulin resistant states) and complications.
While most nominees are anticipated to focus on advancing existing discoveries into pre–clinical and early–stage clinical research (‘bench–to–bedside’), ADA also strongly encourages innovative later–stage translational research (bedside–to–community) where feasible. Applications focused on a single clinical trial are out of scope.
Amount per Award: Up to $1.625 million Dependent on program
Duration of Award: 5 – 7 Years Dependent on program
Initiator Award (for researchers in postdoctoral training)
Eligible applicants must currently be in research training positions (post-doctoral fellow, research fellowship) and have no more than seven years of research training following terminal doctoral degree. Applicants cannot concurrently hold an NIH K99/R00 grant. Candidates must be identified through institutional nomination; applications will be accepted only from individuals with the appropriate institution support.
Accelerator Award (for early-career diabetes investigators)
Awards are available to early-career diabetes investigators proposing innovative and ambitious diabetes-related research programs. Applicants must hold faculty positions and have demonstrated independent productivity in diabetes research. Applicants may currently hold independent NIH funding (K, U or R awards, including an initial R01/U01) but must not have applied for (regardless of outcome), or received, an R01/U01 renewal or a second R01/U01 award. Candidates must be identified through institutional nomination; applications will be accepted only from individuals with the appropriate institution support.
UW-Madison is allowed a maximum of one nomination in one of the two available Pathway award types.
The Association encourages nomination of individuals from diverse backgrounds, including minority groups that are underrepresented in biomedical research. For the purpose of this program, underrepresented racial and ethnic minority groups are defined as American Indians or Alaska Natives, African Americans, Hispanics or Latinos, and Native Hawaiians or Other Pacific Islanders.
Nominees must have the appropriate full–time position to be eligible for the award at the sponsoring institution (postdoctoral fellow for Initiator, independent faculty appointment for Accelerator).
Nominees are required to devote at least 75% of their total time and effort to research during the funding period. In addition, nominees must devote a specific required percent effort for each of the award types.
Internal Competition Application Instructions
Applications for Internal Review
To submit your application, please email a single PDF to firstname.lastname@example.org:
1) Cover Page with name and contact information of PI, project title, and Pathway award type
2) PI Biosketch in NIH Format (5-page maximum)
3) Abstract (250-word limit)
The abstract must not exceed 250 words. The abstract must be a technical description of the proposed work that includes a background, hypothesis, supporting rationale, specific aims, research design, and relevance to a cure, prevention, and/or treatment of diabetes. The abstract should be written in the third person.
4) Research Strategy (2-3 pages) providing a description of the proposed project addressing the intent of the program solicitation.
Applications are due to ADA by August 01, 2022.